Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP9521 in Metastatic Castrate-resistant Prostate Cancer
NCT01352208Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Mar 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ASP9521 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Safety and Tolerability (AEs, labs, vital signs, ECGs). Started Mar 2011; status: terminated.
02
Drugs
ASP9521
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01352208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352208.